Cell Therapy
Process Development

DES Pharma supports cell therapy manufacturing process development from leukapheresis
qualification and T-cell activation through lentiviral transduction, closed-system manufacturing,
cryopreservation, tech transfer, and PPQ readiness, for autologous and allogeneic programs.

 

Process Development ExpertiseManufacturing Process Design That Reflects the Biology

Cell therapy manufacturing processes are not analogous to recombinant protein production. The product is a living cell population whose critical quality attributes (viability, identity, transduction efficiency, vector copy number, and potency) are established by process decisions made during development, not adjusted downstream.

DES Pharma brings direct process development experience across autologous CAR-T, TCR-T, and TIL programs as well as allogeneic NK and iPSC-derived platforms. Our approach is phase-appropriate and science-driven: we design experiments to answer the questions that matter for the next regulatory milestone. We bring that discipline from first leukapheresis planning through pre-commercial process characterization and BLA submission support.

Phase-Appropriate Services Structured Support at
Every Development Stage

Cell therapy process development must progress with deliberate phase-gating. Early-stage decisions define the commercial process. We help programs make those decisions well from the start.

 

Preclinical / IND Enabling

Foundation-setting studies that inform the IND manufacturing section and establish process feasibility.

Phase 1 / 2 Clinical

Reproducible, documented GMP manufacturing process capable of supporting clinical batch production at CDMO scale.

Pre-Commercial / Phase 3

PPQ readiness and BLA CMC section requiring a robust, characterized process with documented control strategy.

Technical CapabilitiesDepth Across the Cell Therapy Manufacturing Process

Cell therapy process development demands expertise that spans cell biology, clinical operations, and GMP manufacturing. DES Pharma brings that depth across the critical unit operations that define product quality.

Leukapheresis & Starting Material

Starting material specification development, apheresis product assessment criteria, fresh vs. cryopreserved handling decisions, and donor qualification protocols. This variability is the primary source of batch-to-batch inconsistency in autologous manufacturing.

Transduction & Activation

T-cell activation strategy selection (anti-CD3/CD28 beads, TransAct, soluble cytokines), MOI optimization for lentiviral and retroviral transduction, transduction efficiency assessment, VCN targeting, and process parameter bracketing for consistent CAR expression.

Platform Engineering

Scale-up and performance characterization of G-Rex, WAVE bioreactors, Cocoon automated platforms, and CliniMACS Prodigy. Closed-system manufacturing design for reduced contamination risk. Media and cytokine (IL-2, IL-7, IL-15) optimization for target phenotype and expansion efficiency.

Cryopreservation & Formulation

This includes DMSO concentration optimization, cryobag selection, controlled-rate freezing protocol design, and post-thaw recovery characterization. Fill and finish preparation aligned with cryogenic logistics requirements and lot release specifications.

Why DES PharmaWhat We Bring to Your Process
Development Program

Phase-Appropriate Scope Control

We scope process development work to what is needed for the next regulatory milestone, not the eventual BLA. This prevents over-investment in early stages and directs resources where they create the most value.

Autologous vs. Allogeneic Distinction

We do not apply a single manufacturing framework across both autologous and allogeneic programs. The operational constraints and regulatory expectations are fundamentally different, so we consult accordingly.

Platform Technology Familiarity

Direct experience with G-Rex, Cocoon, CliniMACS Prodigy, and WAVE systems means we can advise on platform selection and performance, not just describe them. Equipment choices have lasting regulatory implications.

CMC Documentation Readiness

Process development without documentation generates data, not submissions. We integrate IND authorship, amendment support, and BLA section drafting throughout the development program rather than treating it as a downstream exercise.

CDMO Oversight & Person-in-Plant

When a critical manufacturing run occurs at your CDMO, we ensure it executes as designed, deviations are captured appropriately, and the batch record tells the full story.

Supply-Informed Process Design

Vein-to-vein timelines, cryogenic logistics, and CDMO capacity constraints are process design inputs, not afterthoughts. We design manufacturing processes with the supply chain already in view.

Our Approach

How We Engage on Cell Therapy Process Programs

We begin by understanding your program’s specific context (molecule, stage, regulatory history, and manufacturing model) before recommending a process development strategy.

Clinical Supply Chain Consulting

Program Assessment & Gap Analysis

Review existing process data, IND documentation, and manufacturing history to identify gaps relative to phase-appropriate expectations and your target CBER/OTAT regulatory pathway.

Process Development Roadmap

Define a fit-for-purpose process development plan covering manufacturing platform decisions, characterization milestones, CDMO selection criteria, and regulatory filing timeline, integrated with your clinical plan.

Technical Execution & CDMO Oversight

Our consultants lead, support, or oversee specific workstreams: from writing process protocols and directing CDMO activities to reviewing batch data and resolving deviations in real time.

Regulatory Submission Support

Prepare, review, and respond on IND manufacturing sections, IND amendments, BLA CMC modules, and CBER/OTAT meeting packages, with the documentation quality that reflects positively on your program.

Regulatory References

21 CFR 1271

HCT/P registration & cGTP: chain of identity, donor eligibility, COI/COC documentation for cell therapy products

21 CFR 600

Biological product standards: lot release, potency, and identity requirements applicable to BLA-regulated cell therapies

ICH Q5E

Comparability of biological products: governs process change and site transfer strategies across clinical development

ICH Q5A

Viral safety evaluation: informs RCL/RCR testing strategy and adventitious agent assessment for gene-modified cell products

RMAT

Regenerative Medicine Advanced Therapy: expedited review pathway with enhanced CBER interaction for qualifying cell therapy programs

Get Started Ready to Build a Robust Cell Therapy Manufacturing Process?

From first leukapheresis planning through PPQ and BLA submission,
DES Pharma brings the experience to move your program forward with confidence.